Division of Bristol-Myers Squibb Co.
Latest From iPierian Inc.
Senior executives are to depart Gilead Sciences, Bristol-Myers Squibb and Amgen, while C-suite and board hires have been reported at Sirnaomics, Pandion, Purdue Pharma, Cardurion and OncoSec.
Bioverativ revealed its first transaction since spinning out from Biogen with the acquisition of True North for $400m plus up to $425m in milestone payments. The deal gives Bioverativ a clinical asset, helping to fill the gap between preclinical programs and commercial products in its R&D pipeline.
Biogen agreed to pay $300m upfront to buy a Phase II-ready tau antibody from Bristol. The plan is to move rapidly into mid-stage clinical trials for Alzheimer's disease and progressive supranuclear palsy.
With a focus on specialty drugs, Bristol wants to be known for more than immuno-oncology. To that end, specialty development head Douglas Manion is charged with leading innovation in immunology, virology and cardiovascular, genetically defined and fibrotic disease.
- Therapeutic Areas
- Neurology, Nervous System
- iZumi Bio Inc.
- North America
- Parent & Subsidiaries
- Bristol-Myers Squibb Co.
- Senior Management
Nancy E Stagliano, PhD, CEO
Adam Rosenthal, PhD, VP, Corp. Dev.
- Contact Info
Phone: (650) 872-4700
951 Gateway Blvd.
South San Francisco, CA 94080
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.